Xolair 150 MG/1.2 ML powder VLS
Ended Awarded Last action
- Contract number
- SPE2DR26FQSY2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,951
Award facts
- Contract value 100% obligated
- $18,950.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $18,950.64 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/1.2 ml powder vials. The delivery order, issued on January 29, 2026, with an ultimate completion date of February 20, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was established on November 13, 2025, with a $499.999 billion ceiling value through December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the Department of Defense's global military healthcare supply chain, delivering a comprehensive range of branded and generic prescription medications, biologics, and medical consumables to federal agencies. The company's extensive product portfolio includes specialty pharmaceuticals such as Xolair, an immunosuppressant biologic agent used in the treatment of allergic and autoimmune conditions. As one of multiple regional prime vendor contractors under the broader $30.3 billion PPV-G GEN V acquisition strategy, DMS Pharmaceutical Group has demonstrated substantial performance capability through numerous prior delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division, positioning it as a key provider supporting recurring medical supply needs of military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FQSY2?
SPE2DR26FQSY2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26FQSY2 worth?
The government has obligated $18,951 on SPE2DR26FQSY2.
Is contract SPE2DR26FQSY2 an order under another contract?
Yes. SPE2DR26FQSY2 is a delivery order under SPE2DR25D9214, an indefinite delivery contract.
Was contract SPE2DR26FQSY2 competed?
The extent of competition for SPE2DR26FQSY2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award